Home Archives 2008

Yearly Archives: 2008

Apologies for light posting as of late. I’ve been buried deep in revisions to Building Biotechnology and prepping for an upcoming talk. Writing is coming to a close, so soon I’ll be looking for external reviewers and case study contributions.

For those of you attending BIO 2008, I’ll be presenting in a session on trends in biotechnology communication on Friday morning.

Title: Scientific Communications – Trends and Liabilities
Track: Public Relations/Investor Relations
Date and Time: Friday, June 20 9:00 AM – 10:30 AM

Looking forward to seeing old colleagues and meeting new friends BIO.

I’m also working on an interesting story I want to post on the blog shortly. It’s about the challenges of managing founder/board relations in building a biotechnology company. Stay tuned…

The March 2008 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract of each article:

Volume 14, Issue 2


Yali Friedman


Export compliance for life sciencesPDF
John Avellanet
A new approach to improve technology commercialisation in university medical schoolsPDF
Courtney Price, Richard Huston, Arlen D Meyers
Biotechnology business models work: Evidence from the pharmaceutical marketplacePDF
J Leslie Glick
Valuing biotechnology companies: Does classification by technology type help?PDF
Jacqueline Loh, Robert Brooks
Risk management for the biotechnology industry: A Canadian perspectivePDF
Sandra Vanderbyl, Sherry Kobelak
Singapore’s biomedical sciences landscapePDF
Keat-Chuan Yeoh
Social responsibility for the use of genes, genomes and biotechnology in biotechnology companies: A commentary from the bioethical viewpointPDF
Yoshihiro Okada, Kazuo N Watanabe

Legal and Regulatory Updates

Legal and regulatory updatePDF
Gerry Kamstra, John Wilkinson

Conference Report

Maryland and Virginia unite at 2007 Mid-Atlantic Bio ConferencePDF
Harley King

Book Reviews

Book Review: Stem cell wars: Inside stories from the FrontlinesPDF
Grant H Skrepnek


Courtesy of DrugPatentWatch.com:

Drug Patent Expirations in April 2008
*Drugs may be covered by multiple patents

TradenameApplicantGeneric NamePatent NumberPatent Expiration
ACTINEXUniv Az Cancer Ctrmasoprocol4,695,590APR 17,2008
ACTINEXUniv Az Cancer Ctrmasoprocol5,008,294APR 15,2008
ESTROSTEP 21Warner Chilcottethinyl estradiol; norethindrone acetate5,010,070APR 23,2008
ESTROSTEP FEWarner Chilcottethinyl estradiol; norethindrone acetate5,010,070APR 23,2008
FEMPATCHParke Davisestradiol5,006,342APR 09,2008
LODINE XLWyeth Pharms Incetodolac4,966,768APR 30,2008
ORFADINSwedish Orphannitisinone5,006,158APR 09,2008
ZEMURONOrganon Usa Incrocuronium bromide4,894,369APR 13,2008

Courtesy of DrugPatentWatch.com

Two new biotechnology books:
I’m proud to announce two new books featuring international best practices in biotechnology business development and biotechnology education. These new books respectively empower industry leaders operating in the dynamic biotechnology industry, and help address the global shortage of skilled biotechnology workers.


First Edition, March 2008
Perfect Bound, 342 pages, US$74.95
ISBN: 978-09734676-7-3
Best Practices in Biotechnology Education
22 International Best Practices in K-12, College, Certificate, Master’s, Doctoral, MBA, Distance Education Programs and Student Groups
This international compilation is directed at faculty and program directors seeking to start or expand biotechnology education programs; policy makers and economic developers seeking to meet workforce needs; and, students, scientists, and business professionals looking to enter the biotechnology industry or upgrade their existing skills. The included cases describe a wide variety of international programs from high-school through Ph.D. levels, and student clubs. Some programs are in their first years whereas others are quite mature and have diversified to offer myriad degree and certificate programs.

First Edition, March 2008
Perfect Bound, 186 pages, US$67.95
ISBN: 978-09734676-0-4
Best Practices in Biotechnology Business Development
Valuation, Licensing, Cash Flow, Pharmacoeconomics, Market Selection, Communication, and Intellectual Property
Best Practices in Biotechnology Business Development provides a framework to understand critical issues in biotechnology business development. Experts from a wide range of disciplines have contributed best practices based on their experiences and expertise, enabling biotechnology entrepreneurs, senior managers, directors, and officers to develop a better understanding of the key elements in these operations, empowering them to better manage their implementation.
These books complement my recent title, Building Biotechnology:

Second Edition, August 2006
Hardcover, 320 pages, US$54.95
ISBN: 09734676-3-0
Building Biotechnology
Scientists know science; businesspeople know business.
This book explains both.

As biotechnology changes paradigms in medicine, agriculture, and industrial processes, there is a pressing need for cross-trained individuals capable of developing new innovations and bringing them to market. Building Biotechnology helps readers start and manage biotechnology companies and understand the business of biotechnology. This acclaimed book describes the convergence of scientific, political, regulatory, and commercial factors that drive the biotechnology industry and define its scope.

For more information, contact info@thinkbiotech.com.

Courtesy of DrugPatentWatch.com:

Drug Patent Expirations in March 2008
*Drugs may be covered by multiple patents

TradenameApplicantGeneric NamePatent NumberPatent Expiration
CARDIZEM CDBiovaildiltiazem hydrochloride5,002,776MAR 26,2008
CARDURA XLPfizerdoxazosin mesylate4,837,111MAR 21,2008
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINERBayer Pharmsciprofloxacin4,957,922MAR 18,2008
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINERBayer Pharmsciprofloxacin4,957,922MAR 18,2008
ESCLIMWomen First Hlthcareestradiol4,842,864MAR 25,2008
IFEXBristol Myers Squibbifosfamide4,882,452MAR 03,2008
IFEX/MESNEX KITBristol Myers Squibbifosfamide; mesna4,882,452MAR 03,2008
NEXIUMAstrazenecaesomeprazole magnesium4,738,974MAR 01,2008
NEXIUMAstrazenecaesomeprazole magnesium4,783,974MAR 01,2008
RESCULAR Tech Ueno Ltdunoprostone isopropyl5,151,444MAR 19,2008
SEMPREX-DUcb Incacrivastine; pseudoephedrine hydrochloride4,650,807MAR 26,2008
TOPROL-XLAstrazenecametoprolol succinate4,957,745MARVariationen von <a href=”http://www.pokergrand.de/beste-online-strip-poker-download-wettkonto-pages.html” mce_href=”http://www.pokergrand.de/beste-online-strip-poker-download-wettkonto-pages.html”>strip poker download</a>. 18,2008
TOPROL-XLAstrazenecametoprolol succinate5,001,161MAR 18,2008
TOPROL-XLAstrazenecametoprolol succinate5,081,154MAR 18,2008
UVADEXTherakosmethoxsalen4,999,375MAR 12,2008
VIVELLENovartisestradiol4,814,168MAR 04,2008
VIVELLENovartisestradiol4,994,267MAR 04,2008
VIVELLENovartisestradiol4,994,278MAR 04,2008
VUSIONBarriermiconazole nitrate; petrolatum, white; zinc oxide4,911,932MAR 27,2008

Courtesy of DrugPatentWatch.com

Guest content from John Avellanet, managing director and principal of Cerulean Associates:

John Avellanet

Follow-on biologics are a foregone conclusion in the US. Too much money is at stake. The more difficult discussion starts with how to prepare your company to compete.

Science Succumbs to Dollars
The financial pull on reimbursement organizations and the constituent push on Congress for less expensive biotechnology treatments will inevitably lead to a regulatory approval pathway for so-called follow-on or generic biologics.

I’ll be at Rutgers on February 29th, giving a talk on biotechnology entrepreneurship. My objective is to dispel the popular notions about how biotechnology entrepreneurship occurs, and to provide case studies demonstrating the diversity of methods by which biotechnology entrepreneurs start and build their businesses. I’ll also provide some case studies of significant mis-steps, with the intention of demonstrating that risks can come from many sources.

For more information, visit http://aesop.rutgers.edu/~dgenes/events.html or contact the organizers at dgenes@eden.rutgers.edu

The following appeal for generic biologic legislation was sent in from Insmed via youtube.

I’ve posted previously on the challenges of developing a framework for generic biologic approvals and questioned how much we can really expect to save. In the editorial for the upcoming issue of the Journal of Commercial Biotechnology, I argue that the United States is unlikely to lead in generic biologic regulation.

Got any ideas to overcome the challenges? I’d love to post them here or at the Journal of Commercial Biotechnology.